Oramed will release its PhII data for insulin pill this week; Medac Pharma submits NDA for arthritis injection;

> Medac Pharma had its NDA accepted by the FDA for a subcutaneous injectable methotrexate and injection device for arthritis. More

> Oramed is set to announce the results of a Phase IIa trial for oral insulin this week. Release

> 3-D Matrix filed a patent infringement complaint against Menicon and B-Bridge International for its self-assembling peptide technology. Release

> Researchers in Iran published a study in the journal RSC Advances that shows the utility of a biodegradable heparin-coated nanocomposite system for targeted drug delivery to tumors. Abstract

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.